Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal
By Gina Kim · April 17, 2025, 11:37 PM EDT
Novartis must produce certain privileged documents to Incyte concerning its understanding of their contract for royalty payments from sales of Incyte's blood cancer drug, unless Novartis agrees its former outside counsel,...
To view the full article, register now.